ACTICOAT◊ antimikrobielle Wundauflagen

Eine einzigartige Zusammensetzung mit nanokristalliner Silber-Technologie (NCS-Technologie) sorgt für eine langanhaltende antimikrobielle Wirkung für bis zu 7 Tage auf akuten und chronischen Wunden sowie Verbrennungen.*1-4

840x840-PX-ACTICOAT-Global.png

Sicher behandeln

Ein grosser Oberflächenbereich mit NCS-Struktur ermöglicht die langanhaltende Freisetzung von Silber in die Wundflüssigkeit und trägt so bei Verwendung mit einem geeigneten Sekundärverband dazu bei, eine feuchte Umgebung zu fördern und zu erhalten. Setzt nachweislich ausreichend Silber in gleichbleibender Konzentration frei, um bakterizid zu bleiben.**4-11

Product feature

Evidence, case studies and testimonials

Haftungsausschluss

*Je nach Verbandauswahl. Die ACTICOAT Wundauflage ist bis zu 3 Tage anwendbar. Die ACTICOAT 7 Wundauflage ist bis zu 7 Tage anwendbar.

**Wie in vitro nachgewiesen.

Citations
  1. Smith+Nephew 2008.Silver release testing of Project Andorra (7 day) dressings. Internal Report. DS/08/062/R1.
  2. Smith+Nephew 2009.Silver release testing of ACTICOAT Flex 3 and Silverlon dressings. Internal Report. DS/08/078/R2.
  3. Smith+Nephew 2008.Silver release testing of ACTICOAT Flex 7 dressings. Internal Report. DS/08/062/R2.
  4. Smith+Nephew 2017.Silver release properties of ACTICOAT dressings. Internal Report. DS/16/363/R2.
  5. Smith+Nephew 2008.Antimicrobial activity of ACTICOAT Flex 3 against a broad spectrum of wound pathogens. Internal Report. DOF 0810016.
  6. Smith+Nephew 2008.Antimicrobial activity of ACTICOAT Flex 3 dressings in a 3 day repeat challenge test. Internal Report. DOF 0810017.
  7. Smith+Nephew 2008.Antimicrobial activity of ACTICOAT Flex 7 against a broad spectrum of wound pathogens. Internal Report. DOF 0810012.
  8. Smith+Nephew 2008.Antimicrobial activity of ACTICOAT Flex 7 dressings in a 7 day repeat challenge test. Internal Report. DOF 0810013.
  9. Smith+Nephew A 17-Day wound healing study in full-thickness wounds in minipigs. Internal Statement.
  10. Wright JB, Lam K, Burrell RE. Wound management in an era of increasing bacterial antibiotic resistance: A role for topical silver treatment. Am J Infect Control. 1998;26(6):572 - 577.
  11. Wright JB, Lam K, Hansen D, Burrell RE. Efficacy of topical silver against fungal burn wound pathogens. Am J Infect Control. 1999;27(4):344 - 350.
  12. Cuttle L, Naidu S, Mill J, et al. A retrospective cohort study of Acticoat versus Silvazine in a paediatric population. Burns. 2007;33(6):701 - 707.
  13. Smith+Nephew 2020.ACTICOAT Classic (ACTICOAT 3) PMCF Activity Summary Report. Internal Report. EO.AWM.PCS105.001.v2.
  14. Smith+Nephew 2020.ACTICOAT 7 PMCF Activity Summary Report. Internal Report. EO.AWM.PCS105.002.v2.
  15. Smith+Nephew 2020.ACTICOAT FLEX 3: PMCF Activity Summary Report. Internal report. EO.AWM.PCS105.003.v2.
  16. Smith+Nephew 2020.ACTICOAT FLEX 7: PMCF Activity Summary Report. Internal report. EO.AWM.PCS105.004.v2.
  17. Gago M, Garcia F, Gaztelu V, et al. A comparison of three silver-containing dressings in the treatment of infected, chronic wounds. Wounds. 2008;20(10):273 - 278.
  18. Demling RH, Desanti L. The rate of re-epithelialization across meshed skin grafts is increased with exposure to silver. Burns. 2002;28(3):264 - 266
  19. Smith+Nephew 2008.ACTICOAT Flex 3 has antimicrobial activity in 30 minutes. Internal Report. DOF 0810018.
  20. Smith+Nephew 2008.ACTICOAT Flex 7 has antimicrobial activity in 30 minutes. Internal Report. DOF 0810014.
  21. Yin HQ, Langford R, Burrell RE. Comparative evaluation of the antimicrobial activity of ACTICOAT Antimicrobial Barrier Dressing. J Burn Care Rehabil. 1999;20(3):195 - 200.
  22. Wright JB, Hansen D, Burrell RE. The comparative efficacy of two antimicrobial barrier dressings: In vitro examination of two controlled release of silver dressings. Wounds. 1998;10(6):179 - 188.
  23. Glik J, Labus W, Kitala D, et al. A 2000 patient retrospective assessment of a new strategy for burn wound management in view of infection prevention and treatment. Int Wound J. 2018;15(3):344 - 349.
  24. Muangman P, Chuntrasakul C, Silthram S, et al. Comparison of Efficacy of 1% Silver Sulfadiazine and Acticoat for Treatment of Partial-Thickness Burn Wounds. J Med Assoc Thai. 2006;89(7):953 - 958.
  25. Huang Y, Li X, Liao Z, et al. A randomized comparative trial between Acticoat and SDAg in the treatment of residual burn wounds, including safety analysis. Burns. 2007;33(2):161 - 166.
  26. Tredget EE, Shankowsky HA, Groenveld A, Burrell RE. A matched-pair, randomised study evaluating the efficacy and safety of ACTICOAT silver-coated dressing for the treatment of burn wounds. J Burn Care Rehabil. 1998;19(6):531 - 537.
  27. Tonkin C, Wood F. Nanocrystalline silver reduces the need for antibiotic therapy in burn wounds. Primary Intention. 2005;13(4):163 - 168.
  28. Acar A, Uygur F, Diktas H, et al. Comparison of silver-coated dressing (Acticoat), chlorhexidine acetate 0.5% (Bactigrass) and nystatin for topical antifungal effect in Candida albicans-contaminated, full-skin-thickness rat burn wounds. Burns. 2011;37(5):882 - 885.
  29. Selcuk CT, Durgun M, Ozalp B, et al. Comparison of the antibacterial effect of silver sulfadiazine 1%, mupirocin 2%, Acticoat and octenidine dihydrochloride in a fullthickness rat burn model contaminated with multi drug resistant Acinetobacter baumannii. Burns. 2012;38(8):1204 - 1209.
  30. Ulkur E, Oncul O, Karagoz H, Yeniz E, Celikoz B. Comparison of silver-coated dressing (Acticoat), chlorhexidine acetate 0.5% (Bactigrass), and fusidic acid 2% (Fucidin) for topical antibacterial effect in methicillin-resistant Staphylococcicontaminated, full-skin thickness rat burn wounds. Burns. 2005;31(7 ):874 - 877.
  31. Burrell RE, Heggers JP, Davis GJ, Wright JB. Efficacy of silver-coated dressings as bacterial barriers in a rodent burn sepsis model. Wounds. 1999;11(4):64 - 71.
  32. Strohal R, Schelling M, Takacs M, et al. Nanocrystalline silver dressings as an efficient anti-MRSA barrier: a new solution to an increasing problem. J Hosp Infect. 2005;60(3):226 - 230.
  33. Chaloner D, Stevens J. A comparative study of two silver containing dressings, ACTICOAT 7 and Avance, in the treatment of chronic venous ulcers. Paper presented at: WUWHS; 2004; Paris.
  34. Orsini J, Mainardi C, Muzylo E, et al. Microbiological Profile of Organisms Causing Bloodstream Infection in Critically Ill Patients. Clin Med Res. 2012;4(6):371 - 377.
  35. Smith+Nephew 2008.Antimicrobial activity of ACTICOAT Flex 3 against pathogenic wound pathogens. Internal Report. DOF 0812023.
  36. Smith+Nephew 2008.Antimicrobial activity of ACTICOAT Flex 7 against pathogenic wound pathogens. Internal Report. DOF 0812022.
  37. Smith+Nephew 2005.Investigation into the ability of ACTICOAT and ACTICOAT Absorbent to prevent the formation of bacterial biofilms in vitro. Internal Report. DOF 0512011.
  38. Smith+Nephew 2008.ACTICOAT Flex prevents the formation of biofilms. Internal Report. DOF 0812024.
  39. Driffield K, Woodmansey E, Floyd H. The use of silver-containing dressings to prevent biofilm formation by single and mixed bacterial flora. Paper presented at: Symposium on Advanced Wound Care; 2006; San Antonio, Texas.
  40. Heggers JP, Goodheart MLT, Washington J, et al. Therapeutic Efficacy of Three Silver Dressings in an Infected Animal Model. Journal of Burn Care and Rehabilitation. 2005;26(1):53 - 56.
  41. Guthrie HC, Martin KR, Taylor C, et al. A pre-clinical evaluation of silver, iodine and Manuka honey based dressings in a model of traumatic extremity wounds contaminated with Staphylococcus aureus. Injury. 2014;45(8):1171 - 1178.
  42. Thomas S, Mccubbin P. A comparison of the antimicrobial effects of four silvercontaining dressings on three organisms. Wound Care. 2003;12(2):101 - 107.
  43. Smith+Nephew 2018.A reduced bacterial count reduces the levels of MMP, which are causative of prolonged/chronic inflammation. Internal Report. EO.AWM.PCSgen.003.v1
  44. Westaim Biomedical 2000.Long term comparative evaluation of Silverlon and ACTICOAT 7 dressings activities against MRSA. Fort Saskatchewan, Alberta, Canada. Report - 001213.
  45. Westaim Biomedical 2001.Seven day efficacy of ACTICOAT 7 dressing against multiple organisms. Fort Saskatchewan, Alberta, Canada. Report - 010322.

Title

Text

Explore